Anavex Life Sciences is a clinical stage biopharmaceutical company engaged in the development of therapeutics by applying medicine to central nervous system diseases. Co.'s proprietary SIGMACEPTOR Discovery Platform produced small molecule drug candidates with certain modes of action, based on its understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer's disease, as well as of neurodevelopmental nature, like Rett syndrome. Compounds that have been subjects of Co.'s research include the following: ANAVEX®2-73 (blarcamesine), ANAVEX®3-71, ANAVEX®1-41, and ANAVEX®1066, ANAVEX®1037. The AVXL stock yearly return is shown above.
The yearly return on the AVXL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AVXL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|